IP Library Granted Patent US 7,410,644
Granted Patent B2
US 7,410,644 · App. 10/197,127 · Granted Aug 12, 2008

Recombinant pox virus for immunization against tumor-associated antigens

Assignee: The United States of America as represented by the Department of Health and Human Services
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,410,644
App. No.
10/197,127
Granted
Aug 12, 2008
Kind
B2
Abstract

Recombinant pox viruses capable of expressing cell-encoded, tumor-associated antigens are disclosed. The recombinant viruses are useful for evoking an immune response against the antigen.

Claims (9)

1. A method of treating a mammalian host having a tumor expressing a tumor associated antigen (TAA) by enhancing an immune response to the TAA, comprising administering to the host a first pox virus vector system encoding a tumor associated antigen (TAA) in conjunction with a gene encoding B7.1, wherein both the TAA and the B7.1 genes are expressed, and at least one to three months thereafter administering a second pox virus vector system encoding the same TAA as the first pox virus vector system, in conjunction with a gene encoding B7.1, wherein both the TAA and the B7.1 genes are expressed, wherein the second pox virus vector system is from a different pox virus genus than the first pox virus vector system and the tumor associated antigen is carcinoembryonic antigen (CEA).

2. A method of treating a mammalian host having a tumor expressing a tumor associated antigen (TAA) by enhancing an immune response to the TAA, comprising administering to the host a first pox virus vector system encoding a tumor associated antigen (TAA) in conjunction with a gene encoding B7.1, wherein both the TAA and the B7.1 genes are expressed, and at least one to three months thereafter administering a second pox virus vector system encoding the same TAA as the first pox virus vector system, in conjunction with a gene encoding B7.1, wherein both the TAA and the B7.1 genes are expressed, wherein the first pox virus vector system is from an orthopox virus and the second pox virus vector system is from an avipox virus and the tumor associated antigen carcinoembryonic antigen (CEA).

3. The method of treatment of claim 1 , wherein the first pox virus vector system is from an avipox virus and the second pox virus vector system is from an orthopox virus.

4. The method of claim 2 or 3 , wherein the orthopox is vaccinia and the avipox is fowlpox.

5. The method of claim 1 or 2 , wherein the first pox vector system comprises one pox vector containing DNA encoding both B7.1 and the TAA.

6. The method of claim 1 , wherein the first pox vector system comprises two pox virus vectors, one vector encoding B7.1 and a second vector encoding the TAA.

7. The method of claim 1 or 2 , wherein the second pox vector system comprises one pox vector containing DNA encoding both B7.1 and the TAA.

8. The method of claim 1 , wherein the second pox vector system comprises two pox vectors, one vector encoding B7.1 and a second vector encoding the TAA.

9. The method of claim 1 or 2 , wherein the mammalian host is a human.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 1, 2007
From: SCHLOM, JEFFREY
To: GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 019232/0934 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 15, 2007
From: THERION BIOLOGICS CORPORATION
To: THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 019020/0234 →
Continuity (2)
Continuation 0868628000 · Jul 25, 1996
Related Publication 20030003079A1 · Jan 2, 2003